Literature DB >> 2963926

Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imipramine, amitriptyline and clomipramine.

S Yokota1, Y Ishikura, H Ono.   

Abstract

The cardiovascular effects of various antidepressant drugs including paroxetine, imipramine, amitriptyline and clomipramine, administered intravenously, have been assessed. Paroxetine, imipramine, amitriptyline or clomipramine potentiated the response to norepinephrine (0.1 microgram/kg, i.v.) on systemic blood pressure, while paroxetine, imipramine and amitriptyline weakened the response to tyramine (30 micrograms/kg, i.v.). A marked decrease in systemic blood pressure was observed after large doses of each drug (3 and 10 mg/kg of paroxetine; 1-10 mg/kg of imipramine, amitriptyline or clomipramine); and half of the animals died following administration of 10 mg/kg of imipramine, amitriptyline or clomipramine. Paroxetine did not show a marked effect on heart rate at a dose of up to 3 mg/kg, although 0.1-3 mg/kg of imipramine, amitriptyline or clomipramine dose-dependently caused tachycardia. ECG disturbances were observed in animals administered 10 mg/kg of imipramine, amitriptyline or clomipramine; but in contrast, 10 mg/kg of paroxetine caused only slight changes in the ECG. Prolongation of atrio-ventricular conduction time was observed with all the drugs. It was concluded that the effects of paroxetine on the canine heart are more mild in comparison with other tricyclic antidepressants used, although its pharmacological features are essentially similar to those of other drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963926     DOI: 10.1254/jjp.45.335

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  5 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  Cardiovascular effects of paroxetine.

Authors:  H Kuhs; G A Rudolf
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Paroxetine: a review.

Authors:  M Bourin; P Chue; Y Guillon
Journal:  CNS Drug Rev       Date:  2001

Review 4.  Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  K L Dechant; S P Clissold
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 5.  Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.

Authors:  S M Holliday; G L Plosker
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.